+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
FEMALE
ID07100600

Randomized Study of Trastuzumab Rezetecan With or Without Radiotherapy in HER2-positive Advanced Breast Cancer With Brain Metastases

Led by Henan Cancer Hospital · Updated on 2026-10-13

224

Participants Needed

1

Research Sites

126 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating treatments for women with HER2-positive advanced breast cancer that has spread to the brain. This phase 2 trial compares the use of Trastuzumab Rezetecan combined with radiotherapy to Trastuzumab Rezetecan alone. The goal is to understand which approach better controls the disease and assess safety until the cancer progresses or treatment is no longer tolerated. Participants will be randomly assigned to one of two groups. One group receives Trastuzumab Rezetecan at a dose of 4.8 mgkg every three weeks combined with either fractionated stereotactic radiotherapy or whole brain radiotherapy. The other group receives Trastuzumab Rezetecan alone at the same dosing schedule. Treatment continues until disease progression, intolerable side effects, withdrawal, or study end. During the study, participants will undergo scans and assessments to measure progression-free survival, response rates in the brain and overall tumors, and side effects for up to 1.5 years. Researchers will monitor brain lesions using specific criteria and track adverse events. The total participation time may extend up to several years, including follow-up for safety and effectiveness outcomes.

CONDITIONS

Brief Title

Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here